title: New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease.
abstract: There are an estimated 18 million Alzheimer's disease (AD) sufferers worldwide and with no disease modifying treatment currently available, development of new therapies represents an enormous unmet clinical need. AD is characterized by episodic memory loss followed by severe cognitive decline and is associated with many neuropathological changes. AD is characterized by deposits of amyloid beta (Aβ), neurofibrillary tangles, and neuroinflammation. Active immunization or passive immunization against Aβ leads to the clearance of deposits in transgenic mice expressing human Aβ. This clearance is associated with reversal of associated cognitive deficits, but these results have not translated to humans, with both active and passive immunotherapy failing to improve memory loss. One explanation for these observations is that certain anti-Aβ antibodies mediate damage to the cerebral vasculature limiting the top dose and potentially reducing efficacy. Fc gamma receptors (FcγR) are a family of immunoglobulin-like receptors which bind to the Fc portion of IgG, and mediate the response of effector cells to immune complexes. Data from both mouse and human studies suggest that cross-linking FcγR by therapeutic antibodies and the subsequent pro-inflammatory response mediates the vascular side effects seen following immunotherapy. Increasing evidence is emerging that FcγR expression on CNS resident cells, including microglia and neurons, is increased during aging and functionally involved in the pathogenesis of age-related neurodegenerative diseases. Therefore, we propose that increased expression and ligation of FcγR in the CNS, either by endogenous IgG or therapeutic antibodies, has the potential to induce vascular damage and exacerbate neurodegeneration. To produce safe and effective immunotherapies for AD and other neurodegenerative diseases it will be vital to understand the role of FcγR in the healthy and diseased brain. Here we review the literature on FcγR expression, function and proposed roles in multiple age-related neurological diseases. Lessons can be learnt from therapeutic antibodies used for the treatment of cancer where antibodies have been engineered for optimal efficacy.
authors.affiliation: CNS Inflammation Group, Centre for Biological Sciences, University of Southampton Southampton, UK.
authors.forename: James P
authors.initials: JP
authors.lastname: Fuller
authors.affiliation: Biologics, H. Lundbeck A/S Copenhagen, Denmark.
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Stavenhagen
authors.affiliation: CNS Inflammation Group, Centre for Biological Sciences, University of Southampton Southampton, UK.
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Teeling
keywords: ARIAs; Alzheimer's Disease; Fc receptors; auto-antibodies; cytokines; immunotherapy; neuroinflammation